Cargando…

Recommendations for the treatment of hepatitis C in 2017

The goals of treatment is to eliminate HCV infection, stop or reverse histological changes, reduce the risk of hepatocellular carcinoma development and transmission of the infection to other individuals. According to the recommendation of the Polish Group of Experts for HCV in 2017 all patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halota, Waldemar, Flisiak, Robert, Juszczyk, Jacek, Małkowski, Piotr, Pawłowska, Małgorzata, Simon, Krzysztof, Tomasiewicz, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2017
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497480/ https://www.ncbi.nlm.nih.gov/pubmed/28856290 http://dx.doi.org/10.5114/ceh.2017.67782

Ejemplares similares

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2020
por: Halota, Waldemar, et al.
Publicado: (2020)

Recommendations for the treatment of hepatitis B in 2017
por: Flisiak, Robert, et al.
Publicado: (2017)

Recommendations for the treatment of hepatitis C issued by the Polish Group of HCV Experts – 2016
por: Halota, Waldemar, et al.
Publicado: (2016)

Recommendations for treatment of hepatitis C. Polish Group of HCV Experts – 2015
por: Halota, Waldemar, et al.
Publicado: (2015)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C
por: Domagalski, Krzysztof, et al.
Publicado: (2015)

Distribution of HBV genotypes in Poland
por: Świderska, Magdalena, et al.
Publicado: (2015)

Impact of IL28B and OAS gene family polymorphisms on interferon treatment response in Caucasian children chronically infected with hepatitis B virus
por: Domagalski, Krzysztof, et al.
Publicado: (2016)

Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection
por: Pawlowska, Malgorzata, et al.
Publicado: (2011)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Continuous up to 4 Years Entecavir Treatment of HBV-Infected Adolescents – A Longitudinal Study in Real Life
por: Pawłowska, Małgorzata, et al.
Publicado: (2016)

Vertical genotype 1 HCV infection treated successfully in the second year of life: A case report
por: Pawłowska, Małgorzata, et al.
Publicado: (2012)

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Distribution of HCV Genotypes in the Populations of Inmates in Polish Prison Potulice and Patients Hospitalised in Bydgoszcz
por: Tyczyno, Malgorzata, et al.
Publicado: (2014)

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study
por: Tronina, Olga, et al.
Publicado: (2021)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

Autoimmune reactions in the course of the hepatitis C virus (HCV) infection
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2015)

Effect of hepatitis B virus (HBV) infection on the course of pregnancy and newborns’ health status
por: Łapiński, Tadeusz Wojciech, et al.
Publicado: (2015)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Acute hepatitis A virus infection in patients hospitalized at the Department of Infectious Diseases, Medical University of Lublin (Eastern Poland) in 2017 – a hospital-based retrospective study
por: Krzowska-Firych, Joanna Małgorzata, et al.
Publicado: (2018)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

HBV DNA suppression during entecavir treatment in previously treated children with chronic hepatitis B
por: Pawłowska, M., et al.
Publicado: (2011)

Assessing the consistency of liver fibrosis results obtained through biopsy and transient elastography in patients suffering from chronic hepatitis C
por: Pokora, Agnieszka, et al.
Publicado: (2016)

Tenofovir rescue therapy in chronic hepatitis B patients who failed previous nucleoside analogue treatment
por: Kozielewicz, Dorota, et al.
Publicado: (2015)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Nutrition principles and recommendations in different types of hepatic encephalopathy
por: Pazgan-Simon, Monika, et al.
Publicado: (2016)

The Strategies to Support the COVID-19 Vaccination with Evidence-Based Communication and Tackling Misinformation
por: Rzymski, Piotr, et al.
Publicado: (2021)

The Association of Chronic Hepatitis C with Respiratory Microbiota Disturbance on the Basis of Decreased Haemophilus Spp. Colonization
por: Kosikowska, Urszula, et al.
Publicado: (2016)

Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review
por: Rzymski, Piotr, et al.
Publicado: (2023)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
Publicado: (2018)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q40qg3ip82n1n6320of9b74k59